IFP Advisors’s Filana Therapeutics FLNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12 Hold
10
﹤0.01% 5088
2026
Q1
$17 Hold
10
﹤0.01% 4938
2025
Q4
$20 Hold
10
﹤0.01% 4801
2025
Q3
$29 Hold
10
﹤0.01% 4724
2025
Q2
$18 Sell
10
-5
-33% -$9 ﹤0.01% 4854
2025
Q1
$23 Sell
15
-4
-21% -$10 ﹤0.01% 4148
2024
Q4
$126 Buy
19
+4
+27% +$70 ﹤0.01% 3947
2024
Q3
$441 Sell
15
-250
-94% -$5.76K ﹤0.01% 3158
2024
Q2
$3.27K Buy
265
+1
+0.4% +$21 ﹤0.01% 2697
2024
Q1
$5.36K Sell
264
-200
-43% -$4.61K ﹤0.01% 2437
2023
Q4
$10.4K Sell
464
-8
-2% -$169 ﹤0.01% 2176
2023
Q3
$7.85K Buy
472
+8
+2% +$159 ﹤0.01% 2346
2023
Q2
$11.4K Hold
464
﹤0.01% 2252
2023
Q1
$571 Hold
464
﹤0.01% 3171
2022
Q4
$4K Hold
464
﹤0.01% 3930
2022
Q3
$4K Hold
464
﹤0.01% 4151
2022
Q2
$4K Hold
464
﹤0.01% 3914
2022
Q1
$4K Buy
464
+248
+115% +$10.5K ﹤0.01% 3913
2021
Q4
$12K Buy
216
+2
+0.9% +$105 ﹤0.01% 2162
2021
Q3
$14K Buy
214
+13
+6% +$1.08K ﹤0.01% 2144
2021
Q2
$17K Buy
201
+1
+0.5% +$54 ﹤0.01% 2013
2021
Q1
$9K Buy
+200
New +$7.87K ﹤0.01% 2181

Other funds holding FLNA

IFP Advisors's FLNA Position: Q2 2026 in Review

IFP Advisors held its Filana Therapeutics (FLNA) position steady in Q2 2026 at 10 shares worth $12. The position accounts for ﹤0.01% of the portfolio, ranked #5088.

IFP Advisors first reported a position in FLNA in Q1 2021 and has held it in 22 quarters since. The position peaked at $17K in Q2 2021. 15 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • IFP Advisors held 10 shares of Filana Therapeutics worth $12 as of Q2 2026.
  • IFP Advisors left its Filana Therapeutics share count unchanged in Q2 2026.
  • Filana Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5088 holding.
  • IFP Advisors first reported a position in Filana Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • IFP Advisors's Filana Therapeutics position peaked at $17K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.